IS7268A - Efnafræðilega breytt samtengd mennsk vaxtarhormón - Google Patents

Efnafræðilega breytt samtengd mennsk vaxtarhormón

Info

Publication number
IS7268A
IS7268A IS7268A IS7268A IS7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A IS 7268 A IS7268 A IS 7268A
Authority
IS
Iceland
Prior art keywords
growth hormone
human growth
chemically altered
synthetic human
altered synthetic
Prior art date
Application number
IS7268A
Other languages
English (en)
Inventor
F. Finn Rory
Liao Wei
R. Siegel Ned
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of IS7268A publication Critical patent/IS7268A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS7268A 2001-11-20 2004-05-17 Efnafræðilega breytt samtengd mennsk vaxtarhormón IS7268A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
IS7268A true IS7268A (is) 2004-05-17

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7268A IS7268A (is) 2001-11-20 2004-05-17 Efnafræðilega breytt samtengd mennsk vaxtarhormón

Country Status (25)

Country Link
EP (1) EP1453859A2 (is)
JP (2) JP2005525302A (is)
KR (2) KR20050044858A (is)
CN (1) CN1608079A (is)
AP (1) AP2004003050A0 (is)
AU (1) AU2002356990A1 (is)
BR (1) BR0214451A (is)
CA (1) CA2467731A1 (is)
CO (1) CO5580794A2 (is)
EA (2) EA200700431A1 (is)
EC (1) ECSP045114A (is)
GE (1) GEP20063860B (is)
HR (1) HRP20040448A2 (is)
HU (1) HUP0500997A2 (is)
IL (1) IL162031A0 (is)
IS (1) IS7268A (is)
MA (1) MA27544A1 (is)
MX (1) MXPA04004809A (is)
NO (1) NO20042182L (is)
OA (1) OA13063A (is)
PL (1) PL374354A1 (is)
RS (1) RS53104A (is)
TN (1) TNSN04090A1 (is)
WO (1) WO2003044056A2 (is)
ZA (1) ZA200403907B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
CA2473526C (en) * 2002-01-18 2013-10-22 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
AP2005003246A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
WO2005035553A2 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
ATE542920T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
MX2007007591A (es) * 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
JP2008531482A (ja) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ C末端がpeg化された成長ホルモン
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
JP5508716B2 (ja) 2005-11-08 2014-06-04 アンブルックス,インコーポレイテッド 非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤
CN105384807A (zh) 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
MX2008016169A (es) 2006-07-07 2009-01-15 Novo Nordisk Healthcare Ag Nuevos conjugados de proteina y metodos para su preparacion.
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
PT2272875E (pt) * 2008-04-03 2014-04-28 Biosteed Gene Expression Tech Co Ltd Hormona de crescimento modificada com polietilenoglicol de cadeia dupla, método de preparação e aplicação deste
PL3050576T3 (pl) 2008-04-29 2021-10-25 Ascendis Pharma Endocrinology Division A/S Pegylowane związki rekombinowanego ludzkiego hormonu wzrostu
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
MX2011001167A (es) * 2008-07-31 2011-04-12 Pharmaessentia Corp Conjugados peptido-polimero.
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
US8492503B2 (en) * 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
BR112012014721B1 (pt) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
JP6820841B2 (ja) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション ペグ化インターフェロンのための投薬計画
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric hgh prodrugs
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
CN107405384A (zh) * 2015-03-11 2017-11-28 尼克塔治疗公司 Il‑7部分与聚合物的缀合物
BR112018004208A2 (pt) * 2015-09-18 2018-09-25 University Of Miyazaki derivado de adrenomedulina de longa ação
CN113573698A (zh) 2019-03-04 2021-10-29 阿森迪斯药物内分泌股份有限公司 与每日生长激素相比具有优异功效的长效生长激素剂型
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
CZ300546B6 (cs) * 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
CO5580794A2 (es) 2005-11-30
JP2005525302A (ja) 2005-08-25
RS53104A (sr) 2006-10-27
OA13063A (en) 2006-11-10
EP1453859A2 (en) 2004-09-08
GEP20063860B (en) 2006-06-26
EA008505B1 (ru) 2007-06-29
KR20050044858A (ko) 2005-05-13
WO2003044056A2 (en) 2003-05-30
CN1608079A (zh) 2005-04-20
EA200700431A1 (ru) 2008-02-28
TNSN04090A1 (fr) 2006-06-01
CA2467731A1 (en) 2003-05-30
NO20042182L (no) 2004-08-11
ECSP045114A (es) 2004-07-23
MXPA04004809A (es) 2004-08-11
BR0214451A (pt) 2006-05-30
AP2004003050A0 (en) 2004-06-30
HUP0500997A2 (en) 2007-11-28
EA200400565A1 (ru) 2005-06-30
MA27544A1 (fr) 2005-10-03
WO2003044056A3 (en) 2003-08-21
PL374354A1 (en) 2005-10-17
JP2006321808A (ja) 2006-11-30
ZA200403907B (en) 2007-12-27
KR20070072924A (ko) 2007-07-06
HRP20040448A2 (en) 2006-02-28
IL162031A0 (en) 2005-11-20
AU2002356990A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IS7268A (is) Efnafræðilega breytt samtengd mennsk vaxtarhormón
DK1524272T3 (da) Væksthormonsekretionsfremmere
AU2002342653A8 (en) Modified growth hormone
DE60108654D1 (de) Mähdrescher
DE50210654D1 (de) Mähdrescher
DK1440077T3 (da) Syntetiske heparinpentasaccharider
FI20010694L (fi) Implantti
ATE392508T1 (de) Kunstrasen
DE50209261D1 (de) Mähvorrichtung
NO20024890D0 (no) Implantat
DK1542716T3 (da) Væksthormonfrigivende peptider
FR2815535B1 (fr) Implant pediculaire
DK1333853T3 (da) Vækstfaktorkompleks
DE60131102D1 (de) Monofilamentband
DE60238111D1 (de) Viszeralfettmesser mit tonometer
DE50209070D1 (de) Sämaschine
FR2810231B1 (fr) Cornee synthetique
DE60232967D1 (de) Okulares tränen wachstumsfaktor-ähnliches protein
FR2806309B1 (fr) Implant
ATE392808T1 (de) Mähdrescher
HUP0402334A3 (en) Modified human growth hormone
DE60200268D1 (de) Einkristallzüchtungsverfahren
IS5999A (is) Beinvaxtarörvandi þáttur
FR2825911B1 (fr) Implant cotyloidien
NO20026215L (no) Nytt hormonpreparat